FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W346823> ?p ?o ?g. }

• W346823 abstract "Rheumatoid arthritis (RA) is a chronic, autoimmune joint disease characterized by a massive infiltration of immune cells and synovial lining hyperplasia. This ultimately leads to synovitis, i.e. inflammation of the synovial membrane, and excessive bone loss. Certain bone remodeling components are known to play a key role in the RA pathogenesis: receptor activator of nuclear factor-&#954;B ligand (RANKL), osteoprotegerin (OPG), and dickkopf homolog 1 (DKK1). RANKL is a ligand essential to differentiation of the bone-degrading osteoclasts, while OPG can hinder this by competitive binding of RANKL. DKK1 inhibits activation of the bone-forming osteoblasts. In addition, toll-like receptors (TLRs) are believed to be central in RA. TLRs bind pathogen associated molecular patterns (PAMPs), but also damage associated molecular patterns (DAMPs) found on molecules present in inflamed joints. TLR ligand binding activates production of pro-inflammatory mediators. The exact events and pathways involved in RA are not fully understood. By using the synovial fibroblast (SF) cell line, SW982, as a model for synovitis, this master’s thesis aims to clarify certain signaling events. More specifically, the potential involvement of phospholipase A2 (PLA2) and cyclooxygenase (COX) in expression of bone remodeling genes, in response to TLR agonists and tumor necrosis factor (TNF)-&#945;, was investigated. A known downstream effect of TLR activation is production of the pro-inflammatory cytokine TNF-&#945;. Consequently, TNF-&#945;’s effect on the TLR expression was also studied. Gene expression analysis, by quantitative polymerase chain reaction (qPCR), revealed that the SW982 cells express OPG and DKK1, and probably RANKL. In addition, the cells express TLR1-6, and possibly TLR7 too. It was shown, for the first time, that a TLR1/2 agonist (Pam3CSK4), a TLR2/6 agonist (FSL-1), and a TLR3 agonist (Poly(I:C)), increase the OPG and DKK1 gene expression in SW982 cells. The OPG mRNA increase was also detected at protein level by performing enzyme-linked immunosorbent assay (ELISA). Furthermore, activation of TLR1/2 and TLR2/6 was found to strongly induce IL-6 and COX-2 gene expression. It was discovered that cPLA2 and COX are involved in TLR1/2-mediated induction of DKK1, IL-6 and COX-2 gene expression, and possibly OPG expression. For the TLR2/6-mediated expression of these genes, the involvement of cPLA2 and COX is not as pronounced as for TLR1/2, but still likely. Altogether, these results indicate that the prostaglandin (PG) pathway is triggered upon TLR activation. Besides affecting the mentioned genes, this will lead to increased production of PGs. Prominent PG production is often observed in inflammatory conditions like RA. The activity of PLA2s in response to TLR agonists was studied by radioactivity assays. Activation of TLR1/2, TLR2/6 and TLR3 was found to increase the release of the inflammatory intermediate arachidonic acid (AA) – the first precursor of PG synthesis. Further assays suggested that the GIVA cPLA2 is the main PLA2 responsible for the increase in AA release, with possible involvement of Ca2+-independent PLA2 (iPLA2). Upon investigation of TNF-&#945;’s effects, it was found that the SW982 cells increase their DKK1, TLR2 and TLR3 gene expression. The no-response results for RANKL, OPG, TLR1, and TLR4-7, and the no-response results regarding cPLA2’s involvement, were inconclusive due to non-optimal TNF-&#945; stimulation. In conclusion, even though the bone-protective OPG is up-regulated by TLR activation, this activation may have more negative effects in the context of RA: DKK1, COX-2, IL-6 and AA release are increased, and these are all contributors of joint destruction in RA. In addition, OPG may also exert a negative effect. The protein can prevent apoptosis of SFs and thereby contribute to synovial hyperplasia. Because cPLA2 seems to be involved in the increase of the mentioned components, the enzyme may be an attractive target for reducing inflammatory responses set off by TLRs." @default.
• W346823 created "2016-06-24" @default.
• W346823 creator A5078519365 @default.
• W346823 date "2013-01-01" @default.
• W346823 modified "2023-09-24" @default.
• W346823 title "Effects of Toll-like Receptor Agonists and Tumor Necrosis Factor-α in the SW982 Cell Model for Synovitis" @default.
• W346823 cites W1507322431 @default.
• W346823 cites W1529510901 @default.
• W346823 cites W1541452929 @default.
• W346823 cites W1585634514 @default.
• W346823 cites W1854478470 @default.
• W346823 cites W1888402693 @default.
• W346823 cites W1965412643 @default.
• W346823 cites W1967713105 @default.
• W346823 cites W1969701195 @default.
• W346823 cites W1969790876 @default.
• W346823 cites W1971799655 @default.
• W346823 cites W1974545869 @default.
• W346823 cites W1975777695 @default.
• W346823 cites W1981642161 @default.
• W346823 cites W1982883927 @default.
• W346823 cites W1993038652 @default.
• W346823 cites W1993823509 @default.
• W346823 cites W1994089933 @default.
• W346823 cites W1997131908 @default.
• W346823 cites W1997764369 @default.
• W346823 cites W1999642972 @default.
• W346823 cites W2000468514 @default.
• W346823 cites W2000897989 @default.
• W346823 cites W2002118839 @default.
• W346823 cites W2003208357 @default.
• W346823 cites W2006223248 @default.
• W346823 cites W2011828467 @default.
• W346823 cites W2012238059 @default.
• W346823 cites W2015029046 @default.
• W346823 cites W2023910122 @default.
• W346823 cites W2024175 @default.
• W346823 cites W2025961714 @default.
• W346823 cites W2027542254 @default.
• W346823 cites W2029910909 @default.
• W346823 cites W2031808440 @default.
• W346823 cites W2032362610 @default.
• W346823 cites W2033117797 @default.
• W346823 cites W2035625155 @default.
• W346823 cites W2036612597 @default.
• W346823 cites W2039057018 @default.
• W346823 cites W2040781140 @default.
• W346823 cites W2041747503 @default.
• W346823 cites W2041930998 @default.
• W346823 cites W2042316145 @default.
• W346823 cites W2042408524 @default.
• W346823 cites W2046862489 @default.
• W346823 cites W2049414733 @default.
• W346823 cites W2051026238 @default.
• W346823 cites W2060676927 @default.
• W346823 cites W2062075330 @default.
• W346823 cites W2062697678 @default.
• W346823 cites W2063017680 @default.
• W346823 cites W2065806996 @default.
• W346823 cites W2068294577 @default.
• W346823 cites W2068398404 @default.
• W346823 cites W2070163108 @default.
• W346823 cites W2072606718 @default.
• W346823 cites W2074072621 @default.
• W346823 cites W2078836325 @default.
• W346823 cites W2080056923 @default.
• W346823 cites W2092974646 @default.
• W346823 cites W2097624227 @default.
• W346823 cites W2099055798 @default.
• W346823 cites W2099249565 @default.
• W346823 cites W2105332564 @default.
• W346823 cites W2107277218 @default.
• W346823 cites W2107773968 @default.
• W346823 cites W2110478912 @default.
• W346823 cites W2117963070 @default.
• W346823 cites W2120258455 @default.
• W346823 cites W2122427056 @default.
• W346823 cites W2123665246 @default.
• W346823 cites W2127348328 @default.
• W346823 cites W2131060092 @default.
• W346823 cites W2136918013 @default.
• W346823 cites W2143660712 @default.
• W346823 cites W2145387531 @default.
• W346823 cites W2148172224 @default.
• W346823 cites W2149026148 @default.
• W346823 cites W2149548143 @default.
• W346823 cites W2155702314 @default.
• W346823 cites W2158734690 @default.
• W346823 cites W2161425478 @default.
• W346823 cites W2164845121 @default.
• W346823 cites W2166083002 @default.
• W346823 cites W2169288408 @default.
• W346823 cites W2171264448 @default.
• W346823 cites W2175882437 @default.
• W346823 cites W54929914 @default.
• W346823 cites W2171047928 @default.
• W346823 cites W2461392396 @default.
• W346823 hasPublicationYear "2013" @default.
• W346823 type Work @default.
• W346823 sameAs 346823 @default.

• next